EVER-PHARMA-GMBH
After successfully launching the D-mine ® Pump, an infusion device designed to provide precise continuous subcutaneous drug delivery for Parkinson´s patients, EVER Pharma developed an App to support the training needs of Healthcare Professionals and caregivers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005103/en/
EVER Pharma, a specialist in neurological diseases, offers a complete therapy package for Parkinson’s disease with D-mine ® Pump , D-mine ® Pen and Dacepton® (Dopaceptin® , Apomorphine hydrochloride) and with its new D-mine ® Pump TRAINING APP a simulation tool to support the training and the programing of the D-mine ® Pump.
The App can be easily downloaded and installed onto Android or iOS devices by Healthcare Professionals or caregivers who are working with the D-mine ® Pump and managing the therapy of Parkinson´s patients with infusion therapy.
“With the development of the TRAINING APP for the D-mine ® Pump in Parkinson's therapy, we now have an empowering and interactive tool to support the training of the Healthcare Professionals and caregivers on how to use and program the infusion pump device. The App is an intuitive, easy-to-use simulator and enables training any time everywhere”, explains Georges Kahwati, General Manager at EVER Pharma GmbH.
For more information please visit www.d-minecare.com .
About EVER Pharma GmbH
EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production and commercialization of products in the areas of neurology, critical care, anesthesia and oncology.
From its global headquarters in Austria, Ever Pharma provides innovative therapies and value-added formulations aimed at enhancing patient and healthcare professional’s lives through improved safety and convenience.
The products are developed and manufactured at EU GMP certified facilities in Austria and Germany. The technical operations are highly specialized in the production of complex injectables including high potency substances, crystal suspensions, oily solutions and controlled substances in vials, pre-filled syringes, cartridges, ampoules and implants. EVER markets its products in more than 80 countries around the world through 30 international affiliated companies and strategic partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005103/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
SES Delivers Solid 9 Months and Q3 2025 Results6.11.2025 07:30:00 CET | Press release
SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted EBITDA(2) of €849 million (+11.0% yoy(1)) Networks (+36.3% yoy(1)) supported by growth in Aviation and Government; Media (+0.7% yoy(1)) with important new long-term renewals signed Solid progress with company integration and synergy execution since Day 1 of transaction closure €1.4 billion of new business and contract renewals signed YTD 2025 – with a total combined gross backlog of €7.1 billion O3b mPOWER satellites 9 &10 successfully launched on 22 July, expected to be in service beginning 2026 – boosting O3b mPOWER network capacity and resilience Collected c.$87 million regarding insurance claim for O3b mPOWER satellites 1-4 w
Transition Industries and Mitsubishi Gas Chemical Sign Agreement for the Purchase and Sale of Ultra-Low Carbon Methanol6.11.2025 05:00:00 CET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, signed a long-term methanol sales and purchase agreement with Mitsubishi Gas Chemical Company, Inc. (MGC) for the offtake of ultra-low carbon methanol. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105695992/en/ Masahiko Naito, Division Director of Mitsubishi Gas Chemical and Rommel Gallo, CEO of Transition Industries sign agreement in Tokyo, November 6, 2025 Under the Agreement, which will become effective upon the Project’s Final Investment Decision (FID), Transition Industries will supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,130 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2029. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corpora
Kinaxis Announces Normal Course Issuer Bid5.11.2025 23:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper® Wins Dual CES 2026 Innovation Awards® for its Breakthrough Tech Accessories5.11.2025 22:45:00 CET | Press release
Hyper’s HyperSpace™ Trackpad Pro and HyperDrive® Next USB4 M.2 PCIe Enclosure named as CES Innovation Awards® 2026 Honorees Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom